Blueprint medicines corporation (BPMC)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Revenues:
Total revenues

6,167

51,533

9,139

5,110

730

1,033

1,095

41,439

954

1,628

8,068

5,890

5,840

7,691

6,160

7,065

6,856

4,635

3,426

2,687

652

-

-

-

-

Cost and operating expenses
Cost of sales

24

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

84,146

88,646

81,453

87,101

74,250

70,532

64,562

58,573

49,954

43,629

39,300

33,271

28,487

24,073

18,150

21,273

17,635

16,432

11,681

11,243

9,232

11,333

8,368

6,762

5,381

Selling, general and administrative

35,655

32,265

25,647

21,923

16,553

13,643

12,041

12,333

9,911

8,092

7,378

6,833

5,683

4,991

4,893

4,688

4,646

3,624

4,222

3,840

2,770

2,960

1,921

1,437

1,572

Total cost and operating expenses

119,825

120,911

107,100

109,024

90,803

84,175

76,603

70,906

59,865

51,721

46,678

40,104

34,170

29,064

23,043

25,961

22,281

20,056

15,903

15,083

12,002

14,293

10,289

8,199

6,953

Other income (expense):
Interest income (expense), net

2,904

11,014

6

2

2,710

10,497

14

23

32

3,026

47

59

72

91

109

129

140

161

171

179

185

152

120

89

92

Other income (expense), net

-201

-7,983

3,692

4,235

-44

-7,815

2,799

2,442

2,394

-2,316

954

861

425

201

158

131

61

7

6

-405

-37

-23

-94

1

18

Total other income

2,703

3,047

3,686

4,233

2,666

2,820

2,785

2,419

2,362

1,066

907

802

353

110

49

2

-79

-154

-165

-584

-222

-175

-214

-88

-74

Net loss

-110,955

-66,331

-94,275

-99,681

-87,407

-80,322

-72,723

-27,048

-56,549

-49,027

-37,703

-33,412

-27,977

-21,263

-16,834

-18,894

-15,504

-15,575

-12,642

-12,980

-11,572

-14,468

-10,503

-8,287

-7,027

Other comprehensive loss:
Unrealized gain (losses) on available-for-sale investments

2,492

-157

-287

845

270

174

44

210

-323

-26

89

-200

-114

-45

-28

24

31

-

-

-

-

-

-

-

-

Currency translation adjustments

-27

-29

-3

7

-15

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-108,490

-69,502

-94,565

-98,829

-87,152

-80,164

-72,679

-26,838

-56,872

-49,053

-37,614

-33,612

-28,091

-21,308

-16,862

-18,870

-15,473

-15,575

-12,642

-12,980

-11,572

-

-

-

-

Net loss per share - basic and diluted

-2.11

-1.32

-1.93

-2.04

-1.98

-1.82

-1.66

-0.62

-1.29

-

-0.96

-0.86

-

-

-

-

-

-

-

-

-

-

-

-

-

Reconciliation of net loss applicable to common stockholders:
Net loss

-110,955

-66,331

-94,275

-99,681

-87,407

-80,322

-72,723

-27,048

-56,549

-49,027

-37,703

-33,412

-27,977

-21,263

-16,834

-18,894

-15,504

-15,575

-12,642

-12,980

-11,572

-14,468

-10,503

-8,287

-7,027

Convertible preferred stock dividends

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

883

2,270

1,905

1,313

1,298

1,249

Net loss applicable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-15,575

-12,642

-13,863

-13,842

-16,373

-11,816

-9,585

-8,276

Net loss per share applicable to common stockholders - basic and diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-0.84

-

-0.62

-0.70

-0.57

6.44

-0.47

-0.81

-8.23

-10.85

-8.13

-6.99

-6.44

Weighted-average number of common shares used in net loss per share - basic and diluted

52,655

49,454

48,921

48,842

44,097

43,996

43,915

43,856

43,700

40,077

39,130

38,775

33,190

28,459

27,251

27,170

27,088

27,333

26,835

17,092

1,681

1,574

1,453

1,371

1,285

Product revenue, net
Total revenues

3,500

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration revenue
Total revenues

2,709

-

-

-

730

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-